Liminatus Pharma LIMN
NASDAQ LIMN
$3.90 +0.11 (+2.90%)
At close: Oct 2, 2026 · 4:00 PM EDT

Liminatus Pharma (LIMN) Return on Capital Employed [ROCE] (2026)

Updated

Liminatus Pharma (LIMN) recorded Return on Capital Employed [ROCE] of -7188.34% in Q2 2026.

Analysis

Liminatus Pharma (LIMN) Return on Capital Employed [ROCE] (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 17.83%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 17.92%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 6.28%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 19.32%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 9.54%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 16.66%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -5.97%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 11.86%
10 Liminatus Pharma 4.37 Mn 4.37 Mn - -7,188.34%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -7,188.34%
API Access

Liminatus Pharma Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=LIMN&period=max&api_key=YOUR_API_KEY